Opsonix Inc Information

Opsonix is developing pathogen-extracting therapies to transform the treatment of blood borne infectious diseases, including sepsis. The company's proprietary expertise is creating engineered pathogen-capture proteins derived from opsonins, which are natural components of our innate immune system that bind all types of infectious invaders and toxins, and thereby enable their clearance from our bodies. Opsonix's lead pathogen-capture protein, FcMBL, is being developed as an extracorporeal therapy that treats blood outside the body to remove a broad range of pathogens and toxins responsible for initiating the sepsis cascade without having to first identify the disease-causing agent.